Evidence map›Paper›PMID 35438825›Full record

ArticleBritish journal of haematology2022

Late relapses in Hodgkin lymphoma - should we search for the needle in the haystack?

Tarec Christoffer El-Galaly, Ingrid Glimelius

Abstract read
In one paragraph

Article in British journal of haematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tarec Christoffer El-GalalyDepartment of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.ORCID 0000-0002-4406-380X
Ingrid GlimeliusDepartment of Immunology, Genetics and Pathology, Section of Oncology, Uppsala University, Uppsala, Sweden.ORCID 0000-0001-6158-3041

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hodgkin lymphoma is among the most curable cancers. For patients in remission for 24 months, residual lifetime becomes close to that of the background population. However, late relapses can occur after several years and, as shown by Andersen et al., the outcomes are not always good. Commentary on: Andersen MD, Hamilton-Dutoit S, Modvig L, Vase M, Christiansen I, Christensen JH, et al. Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma Registry. Br J Haematol 2022;198:50-61.

Indexed as

Hodgkin DiseaseHumansRecurrenceHodgkin lymphomalate toxicityrelapsesurvival

Identifiers

PMID35438825
PMCPMC9324958

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.